CARDIOLOGIST Trial: Artificial Intelligence Enabled Electrocardiogram for Atrial Fibrillation Detection

National Defense Medical Center, Taiwan

Status: Completed

Conditions: Atrial Fibrillation New Onset

Treatments: Other: AI-enabled ECG-based Screening Tool

Study type: Interventional

Funder types: Other

Identifiers

NCT05127460

NDMC2021002

Details and patient eligibility

About

This is a randomized controlled trial (RCT) to test a novel artificial intelligence (AI)-enabled electrocardiogram (ECG)-based screening tool for improving the diagnosis and management of Atrial Fibrillation.

Enrollment: 25,732 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients in emergency department or inpatient department
• Patients had at least 1 ECG
• Patients cared by non-cardiologist

Exclusion criteria

• Patients without history of atrial fibrillation diagnosis.
• Patients without history of long-term NOAC or warfarin usage.
• Patients without history of hemorrhagic stoke or ishemic stroke.
• Patients with low eGFR (<30 ml/min)

Trial design

Primary purpose: Screening

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

25,732 participants in 2 patient groups

Intervention

Experimental group

Description:

Patients randomized to intervention will have access to the screening tool.

Treatment:

Other: AI-enabled ECG-based Screening Tool

Control

No Intervention group

Description:

Patients randomized to control will continue routine practice.